Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $62.2 million.

  • Lineage Cell Therapeutics' Non-Current Assets fell 23.82% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.4 million, marking a year-over-year decrease of 23.82%. This contributed to the annual value of $62.2 million for FY2024, which is 0.57% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Non-Current Assets stood at $62.2 million, which was down 0.57% from $62.6 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Non-Current Assets ranged from a high of $62.6 million in FY2023 and a low of $4.9 million during FY2021.
  • Its 3-year average for Non-Current Assets is $43.5 million, with a median of $62.2 million in 2024.
  • In the last 5 years, Lineage Cell Therapeutics' Non-Current Assets crashed by 31.13% in 2020 and then soared by 1,003.08% in 2023.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Non-Current Assets stood at $5.6 million in 2020, then declined by 13.46% to $4.9 million in 2021, then increased by 16.44% to $5.7 million in 2022, then spiked by 1,003.08% to $62.6 million in 2023, then decreased by 0.57% to $62.2 million in 2024.